Cost variation analysis of disease modifying anti rheumatic drugs in Indian market
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20243025Keywords:
Antirheumatic drugs, Cost analysis, DMARD, DPCO, NPPA, Rheumatoid arthritisAbstract
Background: Rheumatoid arthritis (RA) is a chronic inflammatory disease with systemic complications, necessitating treatment to manage inflammation and prevent joint damage. In India, significant cost discrepancies exist among branded formulations of generic drugs, posing a financial burden on patients and impacting treatment adherence. This study focuses on cost differences of disease modifying anti rheumatic drugs (DMARDs) among Indian brands and advocating strict adherence to drug price control order (DPCO) rules and suggests scheduling non-scheduled drugs under DPCO.
Methods: This observational study analysed the cost of 6 oral DMARDs across 16 tablet formulations using data from National Pharmaceutical Pricing Authority (NPPA) and DPCO ceiling prices 2024. Number of brands per formulation, cost ratios, percentage variations, and DPCO price violations was analysed. Statistical analysis was performed using Microsoft Excel Office 2021, and Zotero was utilized for managing references.
Results: This study highlights significant price variations among DMARDs in the Indian market, with methotrexate 2.5mg exhibiting the highest cost ratio (1:3.63) and percentage cost variation (263.6%). Azathioprine 50mg has the most brands available (23), while sulfasalazine 500mg, sulfasalazine 1000mg, and tofacitinib 11mg are among the formulations with the fewest brands (3 each). Notably, sulfasalazine 500mg and hydroxychloroquine 200mg showed the most frequent instances of pricing violations above DPCO recommendations.
Conclusions: Strict regulation for price control and monitoring should be implemented since the DPCO has not yet achieved its goal of enforcing price ceilings, and non-scheduled drugs should be included under DPCO regulations effectively to enhance adherence to RA therapy.
Metrics
References
Arthur A. Schuna. Rheumatoid Arthritis. In: Joseph TD, Robert LT, Gary CY, Gary RM, Barbara GW, L. Michael Posey, eds. Pharmacotherapy A Pathophysiologic approach. 8th ed. New York, NY: McGraw-Hill; 2011:1583-1597.
Gruber S, Harris B, Hylland S. Rheumatoid arthritis. In: Joseph TD, Gary CY, Stuart TH, Thomas DN, Vicki LE, L. Michael Posey, eds. Dipiro’s Pharmacotherapy A Pathophysiologic approach. 12th ed. New York, NY: McGraw-Hill; 2023:1501-1521.
Mohan, H. Textbook of pathology. 6th ed. Jaypee Brothers Medical Publishers (P) Ltd; 2010:851-853.
Tripathi KD. Essentials of Medical Pharmacology. 8th ed. Jaypee Brothers Medical Publishers (P) Ltd; 2019:227-230.
Harrold LR, Briesacher BA, Peterson DAN, Beard A, Madden J, Zhang F, et al. Cost-related medication nonadherence in older patients with rheumatoid arthritis. J Rheumatol. 2013;40(2):137-43.
Pasma A, Schenk C, Timman R, van ‘t Spijker A, Appels C, van der Laan, et al. Does non-adherence to DMARDs influence hospital-related healthcare costs for early arthritis in the first year of treatment? PloS one. 2017;12(2):e0171070.
Das SC, Mandal M, Mandal SC. A critical study on availability and price variation between different brands: Impact on access to medicines. Ind J Pharmac Sci. 2007;69(1).
Gupta SK. Proposed pharmacoeconomics guidelines for India (PEG-I). IPSOR India Chapter; 2013:79- 100.
Allan GM, Lexchin J, Wiebe N. Physician awareness of drug cost: a systematic review. PLoS Medi. 2007;4(9):e283.
Pharma Sahi Daam. Available at: https://nppaipdms.gov.in/NPPA/PharmaSahiDaam/searchMedicine. Accessed 01 July 2024.
Integrated Pharmaceutical Database Management System 2.0. Available at: https://nppaipdms.gov.in/HISUtilities/dashboard/dashBoardACTION.cnt?groupId=Ng==&dashboardFor=TlBQQQ==&isGlobal=1#. Accessed 01 July 2024.
World Health organization. WHO collaborating centre for drug statistics methodology, 2024. Available at: https://atcddd.fhi.no/atc_ddd_index/. Accessed 01 July 2024.
Mishra A, Mishra PS, Kushwah A, Gupta K. A cost variation comparison among oral anti-migraine drugs available in the Indian market. Int J Pham Pharmac Sci. 2024;16(5):80-3:
Shukla AK, Mehani R. Cost analysis of antiepileptic drugs available in India. Int J Basic Clin Pharmacol 2016;5(4):1636-40.
Sharma H, Kumar A, Kaur S, Singh J, Sharma G. Cost analysis of oral antihypertensive drugs: assessing the effect of Drug Price Control Order in India. Asian J Pharm Clin Res. 2022;15(9):73-6.
Thomas M. Rational drug use and essential drug concept. In: Parthasarthi G, Nyfort-Hasen K, eds. A Textbook of Clinical Pharmacy Practice. 1st ed. Himayatnagar, Hyderabad: Orient Longman; 2004:72-3.
Mahesh PA, Parthasarathi G. Medication Adherence. In: Parthasarthi G, Nyfort-Hasen K, Nahata MC, eds. A Textbook of Clinical Pharmacy Practice. 2nd ed. Himayatnagar, Hyderabad: Orient Blackswan Private Limited; 2012.
Munshi R, Singh V. A cost comparison and cost variation analysis of anti rheumatoid drugs and anti-hypertensive drugs in ayurveda and allopathy. Int J Res Pharmac Sci. 2022;13(1):10-20.
Ansari Z, Nerlekar S, Karia S, Pawar S. Cost analysis of disease modifying anti rheumatic drugs: the Indian scenario. Glob J Res Analy. 2020;9(11):68.
National Pharmaceutical Pricing Authority, Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers. An overview of drug pricing @ NPPA 25 year odyssey, 2022. Available at: https://www.nppaindia.nic.in/uploads/pdf/nppa25yearodysseypdf-cfa0b45752d5a7fdb962fa52fe67c607.pdf. Accessed 01 July 2024.
Sachin P, Balamuralidhara V, Pramod K, Dave AJ, Gujarati R, Shukla A. Need for drug price control in India. Int J Drug Regul Affairs. 2013;1(4):12-18.
Downloads
Published
How to Cite
Issue
Section
